

# HIV PREVENTION LEARNING COMMUNITY



Bimonthly Newsletter

VOL. 9

JUNE 2023



## June Newsletter

### PRIDE MONTH

We love June because that means...it's **Pride Month!** We hope everyone has found resources to support campaigns your clinics and organizations are running this month. There are many great resources out there!

CDC has "[Pride-In-A-Box](#)", a how-to guide with information and resources to support your site's Pride Month activities. You can also find their social media toolkit [here](#).

You can find some other great resources and ideas from [GLSEN](#), [The Trevor Project](#), and [Human Rights Campaign](#).

### MAY LC RECAP

May's LC focused on **PrEP for Adolescents**. Together we discussed what PrEP options are available for adolescents, considerations when working with adolescents, and how newer PrEP options, like on-demand dosing and injectable PrEP, might or might not work for this population.

Some of the persistent concerns discussed included confidentiality when billing insurance, how to keep adolescents engaged in care, and addressing stigma among young people.

Are you interested in providing PrEP for adolescents? Let us know; we would love to help.



## RESOURCES

- [May 2023 LC Slides](#)
- [PrEP and Adolescents: The Role of Providers in Ending the AIDS Epidemic](#)
- [Discussing PrEP during contraceptive counseling](#)

*What's next?*

## SUMMER BREAK

### Summer Break:

- The LC will be taking a break until September 2023
- Stay tuned for more information on the next LC date and topic!
- Have any topic suggestions? Let us know!



## MPOX IN SUMMER 2023

While cases of mpox have decreased since their peak last summer, cases are still occurring. In late April, Chicago began to see an increase in mpox cases (35 cases as of 6/10/23) sparking concerns about the potential for new outbreaks this summer.

Healthcare providers should be vigilant about mpox and take complete patient histories to assess possible exposures or risk factors. If you suspect mpox, you should take a detailed sexual history. Mpox should be considered when determining the cause of a diffuse or localized rash, including among patients who have had mpox previously or who were vaccinated against mpox.

Vaccinations remain one of our best tools to prevent serious mpox infection. [CDC](#) does expect new cases among vaccinated people to occur, which was seen in the Chicago cluster. However, those who have completed their two-dose JYNNEOS vaccine series may experience less severe symptoms than those who have not. Clinicians should discuss [mpox vaccination where appropriate](#).

NYC PTC has two upcoming mpox webinars you can join to learn more. Registration is required and CE will be provided.

- [Wednesday July 12th, 12-1pm EST](#)
- [Tuesday July 18th, 12-1pm EST](#)

Have a clinical question? Check out the clinical consultation line: [www.stdccn.org](http://www.stdccn.org)